Ticagrelor Tablet
Product Images NDC 73190-008

Product Visual Gallery

This gallery contains 20 technical images submitted to the FDA as part of the official labeling for Ticagrelor (NDC 73190-008). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Avkare, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

1 (008 60)

Each tablet contains 90 mg of ticagrelor. This medication is intended for adults only, and the recommended dosage should be followed as indicated on the package insert. It is advised to keep this medication out of reach of children and store it at a temperature between 16°C to 30°C (59°F to 86°F). This product is manufactured by AVKARE in Pulaski, TN, and dispensed with a medication guide by MSN Pharmaceuticals Inc. in Piscataway, NJ. For more information, visit the AVKARE website.*

FDA Label Image

Tica-tabs-fig-01 (Tica Tabs Fig 01)

FDA Label Image

Tica-tabs-fig-02 (Tica Tabs Fig 02)

FDA Label Image

Tica-tabs-fig-03 (Tica Tabs Fig 03)

FDA Label Image

Tica-tabs-fig-04 (Tica Tabs Fig 04)

FDA Label Image

Tica-tabs-fig-05 (Tica Tabs Fig 05)

FDA Label Image

Tica-tabs-fig-06 (Tica Tabs Fig 06)

FDA Label Image

Tica-tabs-fig-07 (Tica Tabs Fig 07)

FDA Label Image

Tica-tabs-fig-08 (Tica Tabs Fig 08)

This is a list of medications with recommendations regarding their concomitant usage and potential interactions based on their effects as CYP3A4 inhibitors or inducers. It includes information on drugs like Ketoconazole, Diltiazem, Rifampin, and Desmopressin, specifying whether to avoid concomitant use, adjust dosages, or make no adjustments. The text also mentions medications affecting P-glycoprotein and CYP3A, such as Cyclosporine. Additionally, it briefly touches on the impact of certain drugs on pharmacokinetics parameters like Cmax and AUC.*

FDA Label Image

Tica-tabs-fig-09 (Tica Tabs Fig 09)

This text provides information on the interaction of Ticagrelor with various drugs, indicating whether dose adjustment is needed when co-administered. It includes details on drugs such as Simvastatin, Atorvastatin, Lovonorgestrel, Tolbutamide, Digoxin, Estradiol, and Cyclosporine. This information can be useful for healthcare professionals when considering drug combinations for patients.*

FDA Label Image

Tica-tabs-fig-10 (Tica Tabs Fig 10)

FDA Label Image

Tica-tabs-fig-11 (Tica Tabs Fig 11)

FDA Label Image

Tica-tabs-fig-12 (Tica Tabs Fig 12)

FDA Label Image

Tica-tabs-fig-13 (Tica Tabs Fig 13)

FDA Label Image

Tica-tabs-fig-14 (Tica Tabs Fig 14)

FDA Label Image

Tica-tabs-fig-15 (Tica Tabs Fig 15)

FDA Label Image

Tica-tabs-fig-16 (Tica Tabs Fig 16)

FDA Label Image

Tica-tabs-fig-17 (Tica Tabs Fig 17)

FDA Label Image

Tica-tabs-fig-18 (Tica Tabs Fig 18)

The provided text seems to be a detailed analysis of a clinical trial comparing the effects of Ticagrelor versus placebo on various parameters in patients with ischemic events like strokes and transient ischemic attacks (TIAs). It includes data on patient demographics (age, sex, race), medical history (diabetes, hypertension, prior ischemic events), and outcomes of the treatment with Ticagrelor versus placebo. The text also displays the percentages of patients in each category, such as age groups, sex, and region. The study further shows the Hazard Ratios (HR) and their corresponding 95% Confidence Intervals (CI) for the different outcomes analyzed between the Ticagrelor and Placebo groups. Based on this information, it appears to be a comprehensive evaluation of the efficacy and safety of Ticagrelor in patients with ischemic events.*

FDA Label Image

Tica-tabs-structure (Tica Tabs Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.